Myasthenia Gravis Treatment, Adult, Inpatient, Guideline

5/20/2022

Clinical pathway summary

CLINICAL PATHWAY NAME: Myasthenia Gravis Treatment Guideline

PATIENT POPULATION AND DIAGNOSIS: Patient presenting with generalized weakness, ocular and/or bulbar weakness

APPLICABLE TO: Butterworth and Blodgett hospital

BRIEF DESCRIPTION: Approach to treatment of myasthenia gravis in inpatient settings

OPTIMIZED EPIC ELEMENTS (if applicable):

IMPLEMENTATION DATE: February 2022

LAST REVISED: 5/20/2022

Clinical pathways clinical approach

RATIONALE:
Myasthenia gravis is an auto-immune post-synaptic neuromuscular junction disorder. It is an anti-body mediated, T-cell dependent immunologic attack targeted at proteins in the post-synaptic membrane namely acetylcholine receptors and/or receptor associated proteins. Since it is a T-cell dependent process, thymus is speculated to play a role in dysregulation of self-tolerance and pathogenesis of myasthenia gravis. It is characterized by fatigable weakness of ocular, bulbar, limb and respiratory muscles with varied involvement.

Clinical manifestations
The cardinal feature of myasthenia gravis is fatigable weakness which is typically worse at the end of the day or after exertion/exercise. The weakness involves different muscle groups including ocular, bulbar, limb and respiratory muscles. Clinical symptoms may vary with ptosis, binocular diplopia, dysphagia, flaccid dysarthria, hypophonia, nasal speech, facial weakness, neck flexion/extension weakness, proximal limb weakness, respiratory muscle weakness causing respiratory insufficiency and respiratory failure.
There are two main clinical types of myasthenia gravis namely ocular and generalized flare based on type of muscle involvement. In ocular myasthenia gravis, the weakness is restricted to eyelids and extra-ocular muscles. In generalized flare, there is variable involvement of limb, bulbar, ocular, and respiratory muscles. Common triggers of myasthenia gravis include antecedent illness, physical and emotional stress, medications, surgery, extreme temperatures, pregnancy and menstrual periods.

**Diagnosis**
Diagnosis of myasthenia gravis is based on clinical and serological testing. Bedside tests like ice pack and tensilon tests are sensitive but are not confirmatory for myasthenia gravis due to high false positive rates. Antibodies that are routinely tested for myasthenia gravis include acetylcholine receptor (binding, blocking, and modulating) antibody (AChR-Ab), muscle specific tyrosine kinase antibody (MuSK-Ab), low-density lipoprotein receptor-related protein 4 (LRP4). If the above antibodies are positive, it is known as seropositive myasthenia gravis which account for majority of the cases. There are few cases of seronegative myasthenia gravis in about 6 to 10 percent of the patients. Some patients are seronegative on initial testing and seroconvert on repeat testing after a period of time. Seronegative cases are seen in approximately about 50% of ocular myasthenia and 20% of generalized flare. EMG is a confirmatory test for myasthenia gravis where repetitive nerve stimulation (RNS) reveals greater than 10 percent decrement in compound muscle action potential (CMAP) and single fiber EMG reveals abnormal jitter. CT thorax is also routinely done to evaluate for thymoma which is commonly associated with myasthenia gravis. Thyroid function testing should be performed since myasthenia gravis is associated with other autoimmune disorders, especially autoimmune thyroid disease.

**Treatment**
Myasthenia gravis is often treatable with immunomodulation and thymectomy. The goal of treatment is to achieve remission (no signs or symptoms from myasthenia gravis) or to achieve minimal manifestation status (no subjective symptoms with mild weakness on exam which does not impede normal functioning) with minimal side effects from medications. Treatment is custom made based on their age and comorbidities. Appropriate treatment leads to remission with good prognosis and low mortality rates of <5%.
In patients with mild symptoms or minimal manifestation status, pyridostigmine is the initial choice of symptomatic treatment. If remission is achieved or if symptoms are well controlled on pyridostigmine, recommend clinical monitoring with no additional treatment. 8 Long term immune suppression is considered in severe cases or if symptoms are not well controlled on pyridostigmine or if symptoms recur after a temporary response to pyridostigmine. Oral glucocorticoids are the initial mainstay of immunosuppressants. Comorbidities like uncontrolled diabetes mellitus, weight, avascular necrosis, osteoporosis, elderly population, peptic ulcer disease and psychiatric illness amongst others should be considered prior to initiating corticosteroids. Since high doses of steroids can exacerbate bulbar weakness, they are typically started at lower doses in outpatient settings with slow titration until target dose is achieved.
In patients who require long term immunosuppression and/or corticosteroids are contraindicated, non-steroidal immunosuppressants are used. Mycophenolate mofetil and azathioprine are most used oral long term immunosuppressants. Rituximab is a monoclonal antibody targeted against CD20 given intravenously which is reserved for patients with severe and refractory generalized myasthenia gravis, especially in MuSK positive patients. \(^9,\)\(^10\) Eculizumab is a monoclonal antibody targeted against complement C5 which has recently been approved by FDA for treatment of AChR positive generalized myasthenia gravis.\(^11\)

In patients presenting with myasthenic crisis or impending crisis, short-term rescue immunomodulating treatments like plasma exchange or intravenous immune globulin (IVIG) are utilized. Either of the above treatments can be used based on patient’s comorbidities for a therapeutic 5 plasma exchange treatments over 7-14 days or 2 gm/kg of IVIG over 2-5 days. It is also used as long-term maintenance therapy for refractory patients who cannot tolerate oral immunosuppressants. Patient’s with thymoma should be referred to for surgical resection of thymoma. Thymectomy should be done immediately or as soon as the patient is strong enough after initiating immunomodulatory treatment or after crisis is treated appropriately to undergo surgery.\(^12\) Thymectomy is generally not indicated in patients older than 65 years of age. In patient’s without thymoma, role of thymectomy is controversial. There was a double blinded trial which compared thymectomy plus prednisone with prednisone alone in adult patients with AChR positive generalized myasthenia gravis which demonstrated that thymectomy improves clinical outcome.\(^13\) Avoidance of medications that can exacerbate myasthenia will help avoid developing crisis or impending crisis.
TREATMENT AND MANAGEMENT:

Low suspicion
- See table for criteria
  - Rule out mimickers of MG
    - See table for mimickers
  - Send AChR binding antibody with MUSK reflex
  - Consider trial of Pyridostigmine
  - Consider follow-up with general neurology or neuromuscular in 1 month to follow up on Ab +/- EMG

High suspicion OR confirmed cases
- See table for criteria
  - Send AChR binding antibody with MUSK reflex
  - CT thorax
  - Consider inpatient EMG
  - Treat causes of exacerbation

Ocular Myasthenia*
- * Ocular muscle weakness with normal facial, bulbar and limb muscle strength
  - Start Pyridostigmine 60 mg TID
    - Can titrate up quickly if suboptimal response
    - If severe and unresponsive, consider starting prednisone 10-20 mg daily.
    - F/U with neuromuscular clinic in <3 month

Generalized Myasthenia*
- * Kyphotic spine or ocular or bulbar weakness
  - Start Pyridostigmine 60 mg TID
    - Can titrate up if tolerated
    - If mild symptoms or easily treated with Minimal manifestation status (MMS)*
      - * No symptoms or functional limitations with mild weakness from MG
      - F/U in neuromuscular clinic in 2-4 weeks
    - If continued moderate or severe symptoms
      - Start inpatient IVIG/PLEX
        - Consider starting prednisone 10-20 mg daily or consider non-steroidal immunosuppressants (NSIS) if steroids are contraindicated *
        - * Talk to neuromuscular physician prior to initiating NSIS

Impending crisis* OR Crisis**
- * Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks)
- ** Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation
  - Admit to ICU and start IVIG/PLEX
  - Consider starting prednisone 60 mg daily concurrently with IVIG/PLEX
  - Restart Pyridostigmine once extubated
  - Consider NSIS inpatient if steroids are refractory or contraindicated or high likelihood of complications*
  - * Talk to neuromuscular physician prior to initiating NSIS
  - Message NM team to schedule F/U and to plan if bridging with outpatient IVIG/PLEX is needed
### Low suspicion
- Generalized weakness or fatigability without ocular or bulbar weakness
- Asymmetric features
- Non-fatigable symptoms
- Other causes of weakness/mimickers
  - a) Generalized weakness- Check TSH, stroke evaluation, CK (myopathy)
  - b) Ocular symptoms- CTA head/neck (aneurysms)
- Isolated symptoms
- Normal physical exam
- Chronic or insidious progression

### High suspicion
- Diurnal variance or fatiguability
- >2 classic symptoms:
  - a) Diplopia & ptosis
  - b) Dysesthesia & dysphagia
  - c) Limb weakness & bulbar/ocular symptoms
- Antecedent event- illness, stress, medications
- Subacute worsening

### Considerations for starting steroids
- Diabetes
- Weight
- Avascular necrosis
- Peptic ulcer disease
- Psychiatric disease
- Elderly patients
- Osteoporosis

### Considerations for starting NSIS
- Lymphopenia
- Liver disease (azathioprine)
- Woman of childbearing potential (Cellcept contraindicated in pregnancy)

### Criteria for intubation
- Vital capacity (VC) less than 1 L (or <20-25 ml/kg)
- Negative inspiratory force (NIF) < -30 cm H2O
- Positive expiratory force (PEF) <40 cm H2O
- Recruitment of accessory muscles
- Weak cough
- Difficulty counting to 20 in a single breath
- Respiratory acidosis
- Inadequate secretion clearance

### Considerations for neuromuscular blocking agents
- Depolarizing agents (for example, succinylcholine) are less potent in myasthenics because fewer functional post-synaptic AChR are available. This decrease in receptors also results in a decrease in the safety margin or remaining AChR available for neuromuscular transmission.
- Nondepolarizing agents (for example, vecuronium) have increased potency, and reduced doses are required for paralysis

* (NN) may be used to prevent intubation or reintubation of patients in myasthenic crisis however the evidence is inconsistent

### Medications to avoid
- Telithromycin (Ketek)
- Ciprofloxacin and levofloxacin
- Zithromax (e.g., “Z-pak”)
- Gentamycin, neomycin (aminoglycoside antibiotics; tobramycin may be least offensive)
- Ampicillin
- Macrolides
- Quinolones
- Ciprofloxacin
- Botulinum toxin (e.g., “Botox”)
- Steroids (e.g., prednisone)
- Quinine
- Procainamide
- Magnesium in patients with kidney disease; potentially dangerous if given intravenous
- D-penicillamine
- Beta-blockers
- Calcium channel blockers
Pathway information

OWNERS(S): Anvita Potluri, Yao Cheng, Matthew Ebright, Michelle De Jesus Brazitis

CONTRIBUTOR(S): Anvita Potluri, Yao Cheng, Matthew Ebright, Michelle De Jesus Brazitis

EXPERT IMPROVEMENT TEAM (EIT): Inpatient Neurology/Neuromuscular

CLINICAL PRACTICE COUNCIL (CPC): Neuroscience

CPC APPROVAL DATE: February 18, 2022

OTHER TEAM(S) IMPACTED: Neurohospitalist and neurocritical care services

References: